TCIM
PDLI

TIAA CREF Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

TIAA CREF Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.13M Hold
303,391
– – ﹤0.01% 2261
2018
Q4 		$880K Sell
303,391
-28,719
-9% -$78.9K ﹤0.01% 2330
2018
Q3 		$873K Sell
332,110
-20,509
-6% -$50.3K ﹤0.01% 2489
2018
Q2 		$825K Sell
352,619
-26,376
-7% -$73.6K ﹤0.01% 2571
2018
Q1 		$1.11M Sell
378,995
-87,200
-19% -$238K ﹤0.01% 2388
2017
Q4 		$1.28M Sell
466,195
-224,526
-33% -$690K ﹤0.01% 2348
2017
Q3 		$2.34M Buy
690,721
+247,720
+56% +$689K ﹤0.01% 2074
2017
Q2 		$1.09M Sell
443,001
-5,513
-1% -$12.7K ﹤0.01% 2499
2017
Q1 		$1.02M Sell
448,514
-34,845
-7% -$77.1K ﹤0.01% 2493
2016
Q4 		$1.02M Sell
483,359
-80,511
-14% -$225K ﹤0.01% 2514
2016
Q3 		$1.89M Sell
563,870
-105,120
-16% -$334K ﹤0.01% 2208
2016
Q2 		$2.1M Buy
668,990
+134,215
+25% +$448K ﹤0.01% 2086
2016
Q1 		$1.78M Buy
534,775
+7,559
+1% +$23.6K ﹤0.01% 2139
2015
Q4 		$1.87M Sell
527,216
-6,478
-1% -$27.1K ﹤0.01% 2198
2015
Q3 		$2.68M Sell
533,694
-17,210
-3% -$98.6K ﹤0.01% 1967
2015
Q2 		$3.54M Buy
550,904
+8,156
+2% +$54.6K ﹤0.01% 1928
2015
Q1 		$3.82M Sell
542,748
-15,727
-3% -$114K ﹤0.01% 1815
2014
Q4 		$4.31M Sell
558,475
-31,435
-5% -$249K ﹤0.01% 1729
2014
Q3 		$4.41M Sell
589,910
-9,305
-2% -$86.4K ﹤0.01% 1703
2014
Q2 		$5.8M Sell
599,215
-220,051
-27% -$1.96M ﹤0.01% 1576
2014
Q1 		$6.81M Sell
819,266
-98,436
-11% -$844K ﹤0.01% 1389
2013
Q4 		$7.75M Buy
917,702
+41,580
+5% +$350K 0.01% 1323
2013
Q3 		$6.98M Sell
876,122
-11,631
-1% -$93.5K 0.01% 1339
2013
Q2 		$6.85M Buy
+887,753
New +$6.92M 0.01% 1281

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

TIAA CREF Investment Management's PDLI Position: Q1 2019 in Review

TIAA CREF Investment Management held its PDL BioPharma, Inc. (PDLI) position steady in Q1 2019 at 303,391 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2261.

TIAA CREF Investment Management first reported a position in PDLI in Q2 2013 and has held it in 24 quarters since. The position peaked at $7.75M in Q4 2013. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

  • TIAA CREF Investment Management held 303,391 shares of PDL BioPharma, Inc. worth $1.13M as of Q1 2019.
  • TIAA CREF Investment Management left its PDL BioPharma, Inc. share count unchanged in Q1 2019.
  • PDL BioPharma, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2261 holding.
  • TIAA CREF Investment Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's PDL BioPharma, Inc. position peaked at $7.75M in Q4 2013.
  • 157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.